Q3 2023 Results - Reimagining Medicine slide image

Q3 2023 Results - Reimagining Medicine

Company overview Financial review Conclusions Appendix References FINANCIAL PROFILE Significant improvement in core margin for continuing operations Q3 2023 Core operating Net sales change vs. PY1 income change vs. PY1 Core margin Core margin (in % cc) (in % cc) (%) change vs. PY1 (%pts cc) Net sales change vs. PY1 9M 2023 Core operating income change vs. PY1 Core margin¹ Core margin change vs. PY1 (in % cc) (in % cc) (%) (%pts cc) Continuing operations² 12 21 37.4 2.7 10 19 36.9 2.9 Discontinued operations² 6 -38 10.1 -9.3 8 -11 16.0 -3.7 Group 9 14 33.8 1.3 9 15 34.1 2.0 1. Constant currencies (cc), core results are non-IFRS measures. Explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report 2. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities and Discontinued operations include operational results from Sandoz business. 25 Investor Relations | Q3 2023 Results ✓ NOVARTIS | Reimagining Medicine
View entire presentation